Evelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
21 oct. 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
13 oct. 2021 07h00 HE
|
Evelo Biosciences, Inc.
–Data suggest SINTAX™ medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery– –EDP1867 reduced disease severity and incidence of relapse in murine model of multiple...
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease
27 sept. 2021 02h00 HE
|
Evelo Biosciences, Inc.
–Clinically and statistically significant improvement in PASI-50 score achieved––EDP1815 safety and tolerability data comparable to placebo in study––EDP1815 advancing towards registration studies in...
Evelo Biosciences to Present at 2021 Cantor Global Healthcare Conference
20 sept. 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences Announces Issuance of U.S. Patent for Pharmaceutical Compositions of Single Strains of Naturally Occurring Bacteria as Medicines
09 sept. 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new type of orally delivered medicines, today...
Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors
07 sept. 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights
29 juil. 2021 07h00 HE
|
Evelo Biosciences, Inc.
–EDP1815 Phase 2b data in psoriasis expected in 3Q 2021––Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021––Strengthened leadership team...
Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
22 juil. 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences Announces Grant of Inducement Award
14 juil. 2021 16h01 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced...
Evelo Biosciences Announces Grant of Inducement Award
16 juin 2021 16h01 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced...